← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oxford Biomedical Research, Inc.
Rochester Hills, MI
$4,165,258
Total funding
12
Grants
Funding over time
peak $617.4K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$4,165,258 · 12
By mechanism
R44$2,369,624 · 3
N44$984,909 · 3
R43$725,330 · 5
R41$85,395 · 1
Investigators at Oxford Biomedical Research, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase$617,437
R44 · FY2013 · ES
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase$546,140
R44 · FY2014 · ES
New Award for SBIR Topic 103; Oxford Biomedical, Inc.; Contract No. TBD: Route t$410,915
N44 · FY2009 · ES
HUMAN ISOPROSTANE METABOLITES: DETECTING OXIDANT STRESS$293,994
N44 · FY2000 · ES
DEVELOPMENT OF IMMUNOASSAYS FOR P450 EICOSANOIDS$280,000
N44 · FY2000 · ES
Transcription Factor markers - cellular oxidative stress$250,828
R44 · FY2004 · AG
Transcription Factor markers - cellular oxidative stress$245,186
R44 · FY2003 · AG
Organ Specific Damage Assessment Biomarker Assays$243,888
R44 · FY2003 · ES
Organ Specific Damage Assessment Biomarker Assays$237,818
R44 · FY2005 · ES
Organ Specific Damage Assessment Biomarker Assays$228,327
R44 · FY2004 · ES
A New Co-Expressed P450 and UGT Platform for the Simultaneous Preparation of P450 Metabolites and Their Glucuronides$214,396
R43 · FY2017 · GM
Multidimensional Gas Chromatograph for Toxicological An*$197,185
R43 · FY2001 · ES
Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening$117,685
R43 · FY2011 · ES
NF-KB: A Marker for Cellular Oxidative Stress$99,580
R43 · FY2001 · CA
Molecular Biomarkers/Non-invasive Diagnosis Of Colon CA$96,484
R43 · FY2002 · CA
QCM Quantification of Endocrine Disruptor Activity$85,395
R41 · FY2004 · ES